Sanofi appoints Novartis executive Dr Ameet Nathwani executive VP and CMO
pharmafile | March 10, 2016 | Appointment | Medical Communications |Â Â Â
Sanofi has announced the appointment of Dr Ameet Nathwani as a new member of its Executive Committee, and to the roles of executive vice president and group chief medical officer,effective May 1, 2016. Dr Nathwani joins Sanofi from Novartis, where he served as global head of medical affairs.
Dr Nathwani will be responsible for enterprise-wide medical, patient safety, medical quality assurance, and will insure the highest standard of transparency and compliance in Sanofi’s interactions with healthcare providers, patients and medical organisations, the company says. He will also work with Global R&D and the Global Business Units.
Dr Nathwani succeeds Dr Paul Chew, who has served as senior vice president, chief medical officer since January 2013, and plans to retire later this year.
Sanofi ‘s chief executive, Olivier Brandicourt, comments: “Our industry is experiencing increased pressure to support reimbursement with customised data from real-world evidence, demonstrate ongoing benefit-risk of registered products through continuous scientific data generation, and ensure that data are effectively and transparently communicated. In order to shape Sanofi’s strategy and enhance our world class medical capabilities to address these challenges we have elevated the role of the chief medical officer to the Executive Committee.
“We are very happy to count on Ameet’s strong experience in both development and medical fields. I would also like to take this opportunity to thank Paul Chew for his many valuable contributions to Sanofi. During his long-standing career, Paul has been a highly valued and key Sanofi leader who has demonstrated strong medical leadership.”
A UK citizen, born in Uganda and educated in the UK, Dr Nathwani has more than 20 years’ experience in the pharmaceutical industry, beginning in 1994 when he joined Glaxo Group Research. Between 1994 and 2004, he held increasingly senior global functional and franchise leadership roles in research and development in Glaxo, SmithKline Beecham and GlaxoSmithKline, both in Europe and US.
He joined Novartis in 2004 as senior vice president and global development head of the Cardiovascular and Metabolic Franchise, and over the period of 11 years has held a number of senior development and commercial positions including the global head of the Critical Care Business Franchise. He was appointed as global head of Medical Affairs Novartis Pharma AG in June 2014 and became an extended member of the Pharma Executive Committee where he led the establishment of a Real World Evidence Center of Excellence and Digital Medicine capability.
Dr Nathwani qualified in medicine in 1987 in London, acquired his specialisation in Cardiology at a number of University Hospitals in London, and has a diploma in Pharmaceutical Medicine and an executive Masters in Business Administration.
